UNSPSC 51142020: Acetaminosalol

This classification denotes an analgesic and antipyretic with the molecular formula C15H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3J7H54KMD, chemically known as 2-hydroxybenzoic acid, 4-(acetylamino)phenyl-, ester but generally known as acetaminosalol, which bears US NIH Compound Identifier 1984. European Medicines Agency schedules Acetaminosalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05217MIG. The term ACETAMINOSALOL is an International Non-Proprietary Name.

UNSPSC 51142020 Acetaminosalol is a Commodity code that covers pharmaceutical products, but recent state and local solicitations show activity in naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing rather than acetaminosalol specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local government facilities including Oregon). The work spans the full range of pharmaceutical distribution and procurement—from standalone purchases of emergency medications and drug deactivation systems to large-scale generic pharmaceutical supply agreements with tiered pricing models, compliance certifications, and wholesaler relationships.

Recent opportunities show geographic spread across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2026 (initially listed with a 2023 due date, likely a data entry error). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for self-insured employee and retiree plans—a preliminary information-gathering phase that will inform future RFP development. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with awards effective July 1, 2026, and a two-year initial term.